Referral Letter: Nephrology Evaluation for Mr. xxx Halperin

Date: June 15, 2025
From: Dr. L. yyy, MD
To: Nephrology Department
Subject: Referral for advanced evaluation of chronic kidney disease in the context of complex multi-system comorbidities.

Dear Colleague,

I am referring my long-standing patient, **Mr. xxx W. Halperin**, a 71-year-old retired school principal, for nephrology evaluation in light of **accelerated decline in renal function**, persistent proteinuria, and increasing clinical complexity. Mr. XXXHalperinhas been under my care at Lakeside Family Medicine since 2012 and presents a multifactorial chronic disease picture dominated by progressive diabetic nephropathy, long-standing hypertension, and cardiovascular disease.

Mr. XXXHalperinwas first diagnosed with **type 2 diabetes mellitus in 2008**, following a period of polyuria, fatigue, and fasting blood glucose persistently in the range of 150–180 mg/dL. At the time, his A1c was 7.8%, and he was initiated on metformin monotherapy with lifestyle counseling. He remained stable through 2012, though his glycemic control began to deteriorate gradually despite good dietary adherence. Between 2013 and 2014, his A1c trended upward to 8.3%, and he was transitioned to a basal insulin regimen (glargine) while continuing metformin.

By late 2015, Mr. XXXHalperinbegan to exhibit signs of early diabetic complications. During routine screening that September, **urine microalbuminuria was noted**. Although initially mild, we began ACE inhibitor therapy (lisinopril 10 mg), which he tolerated well. At that point, his serum creatinine was 1.2 mg/dL, and eGFR was approximately 66 mL/min. I continued close monitoring with periodic renal panels.

Over the ensuing years, his **blood pressure became increasingly difficult to manage**, with systolic readings frequently ranging from 140 to 158 mmHg despite monotherapy. In 2017, we added amlodipine to his regimen, which yielded modest improvements.

Throughout 2018 and 2019, Mr. XXXHalperinremained stable, though by late 2019 he began reporting **occasional tingling in both feet**, which was later confirmed as **peripheral neuropathy**. In early 2020, his ophthalmology visit revealed **non-proliferative diabetic retinopathy**. These developments were concerning but not unexpected.

In February 2020, Mr. XXXHalperinpresented to the emergency department with **new-onset chest pressure**, shortness of breath, and elevated troponins. He was diagnosed with a **non-ST elevation myocardial infarction (NSTEMI)** and underwent **coronary angiography with stenting of the LAD**. Post-procedure, his creatinine briefly rose from 1.5 to 1.9 mg/dL (likely

contrast-related), though it resolved within two weeks. He was placed on **dual antiplatelet therapy**, intensified statin dosing, and a beta blocker.

From late 2020 through 2022, his renal markers remained relatively stable (creatinine 1.8–2.0, eGFR ~42–45 mL/min), but his proteinuria increased steadily, with occasional findings in the range of 1.0 to 1.4 g/g. In August 2023, we noted progressive fatigue, worsening exertional dyspnea, and a new onset of bilateral lower extremity edema. An echocardiogram showed preserved ejection fraction but mildly impaired diastolic relaxation. At that point, we initiated a low-dose loop diuretic (furosemide 20 mg daily), which improved his symptoms.

Unfortunately, in April of this year, Mr. XXXHalperinpresented to the ER with **hypertensive urgency** (BP: 202/106 mmHg), fluid overload, and worsening renal indices. He was admitted to St. David's Medical Center and treated with IV antihypertensives and diuretics. His **peak creatinine reached 3.0 mg/dL**, with mild hyperkalemia and metabolic acidosis. He was discharged after 72 hours with stable vitals and a creatinine of 2.4 mg/dL, and I've been following him closely in clinic since.

🏷️ Lab Results — May 28, 2025

Test	Result	Reference Range
Serum Creatinine	2.6 mg/dL	0.6 – 1.2 mg/dL
Estimated GFR	24 mL/min	>60 mL/min
BUN	38 mg/dL	7 – 20 mg/dL
Potassium	5.1 mmol/L	3.5 – 5.0 mmol/L
Urine Protein/Creatinine	1.8 g/g	<0.2 g/g
Hemoglobin	11.6 g/dL	13.5 – 17.5 g/dL
HbA1c (March 2025)	7.3%	<7.0%

💊 Current and Recent Medication Profile

Medication	Dosage	Status	Notes
Metformin	500 mg BID	Active	Continued since 2008
Lantus (glargine)	12 units QHS	Active	Added 2014, dose stable
Lisinopril	20 mg daily	Active	Up-titrated over years, tolerating well
Amlodipine	10 mg daily	Active	Added 2017
Atorvastatin	40 mg at bedtime	Active	Post-MI increase
Furosemide	40 mg daily	Active	Increased post-April hospitalization
Tamsulosin	0.4 mg HS	Active	For BPH
Allopurinol	100 mg daily	Active	Occasional gout flares
Clopidogrel	75 mg daily	Discontinued	Completed 1-year post-stenting course
Ibuprofen	PRN (discontinued)	Discontinued	Renal risk; stopped Dec 2024

Over the course of the past 12 months, Mr. XXXHalperin's renal and cardiometabolic condition has grown more complex. His kidney function, once slowly declining, has entered a steeper trajectory of deterioration. From July 2024 to May 2025, his **creatinine has increased from 2.1 to 2.6 mg/dL**, and **eGFR has fallen below 25 mL/min**. Alongside this, his urine protein excretion has climbed significantly, and he now routinely shows **proteinuria in excess of 1.5 g/g** despite optimized ACE inhibitor therapy.

Clinically, he has begun experiencing **greater day-to-day fatigue**, requiring longer rest periods between basic activities. He reports increased **lower extremity swelling in the evenings**, and in recent weeks has had to reduce his walking distance due to **mild dyspnea on exertion**. He continues to live independently but now struggles with tasks like carrying groceries or navigating stairs without stopping to rest.

During a visit in September 2023, I noted a subtle change in his complexion and demeanor. He expressed frustration about feeling “slower” and more mentally foggy, though he denied syncope, falls, or severe memory issues. Labs at that time showed a mild normocytic anemia (Hgb ~11.8) and slightly elevated potassium, but no acute renal failure. We monitored closely and repeated renal function tests every 6–8 weeks, which continued to show gradual decline.

His **blood pressure management has become increasingly difficult**. Despite consistent use of lisinopril and amlodipine, he continues to present with systolic pressures in the 150s to 160s. We trialed a low dose of hydrochlorothiazide in mid-2024, but this worsened his electrolyte profile and was subsequently discontinued. In April 2025, following a hypertensive emergency, I increased his **furosemide to 40 mg daily**, which has helped control edema but raised concerns about over-diuresis given his reduced renal reserve.

Of note, he was **hospitalized from April 4th to 7th** this year following an ER presentation with **marked fatigue, reduced urine output, and a blood pressure of 202/106**. Labs revealed **acute-on-chronic kidney injury** with a creatinine peaking at 3.0 mg/dL, BUN of 45, and a serum potassium of 5.3. He responded to IV diuretics and careful BP control and was discharged on his previous regimen, albeit with instructions to follow up more closely. Since then, his outpatient creatinine has stabilized in the mid-2s, but his eGFR remains below 30, and his proteinuria is worsening.

As discussed above, pt w/ hx of DM2, HTN, CKD 3b—Cr trending ↑ from 2.1 to 2.6 (see May labs in chart). BP still elevated despite lisinopril 20 mg + amlodipine 10. Pt reports AM lightheadedness, denies falls. Meds: metformin, Lantus, Lasix (↑ to 40 mg daily post-hosp). Labs show proteinuria 1.8 g/g, K+ borderline high at 5.1. Hgb trending low. Hospitalized 4/4–4/7 for HTN emergency—see discharge note. F/U post-discharge okay, Cr back to 2.4. Renal US ordered (appt 6/18). Patient deferred nephrology F/U earlier—daughter’s wedding. Agreed to referral in November 2023.

We discussed a **nephrology referral** at that time, but Mr. XXXHalperinpreferred to wait until after his daughter’s wedding in May, citing stress and travel considerations. He has now agreed that it is time to escalate care to a specialist, particularly in anticipation of further deterioration or dialysis consideration.

Imaging & Diagnostics

A renal ultrasound has been ordered and is scheduled for June 18, 2025, at Southlake Imaging. He has never undergone a renal biopsy, and imaging to date has shown mild cortical thinning but no hydronephrosis or structural abnormalities. Previous echocardiography in 2023 showed preserved left ventricular ejection fraction (~55%), with evidence of diastolic dysfunction, likely contributing to his episodic volume overload. Chest radiographs in September 2023 ruled out overt pulmonary edema, though mild basilar congestion was noted.

Functional & Social Context

Mr. XXXHalperinlives alone in a single-level home. He is widowed and has no daily caregiver, though his daughter visits monthly from Denver. He remains oriented and capable of managing his medications, but he has begun to experience minor lapses in memory — such as forgetting lab appointments or misplacing his glucometer — which he admits are new for him. He has modest retirement savings and is compliant with Medicare Part B.

He cooks for himself and drives short distances. He is fully ambulatory, though he now uses a cane on uneven surfaces due to **right knee osteoarthritis** (s/p knee replacement in 2021). He has stopped traveling beyond his immediate area and has expressed **anxiety about future hospitalizations** and the prospect of dialysis, stating that he "doesn't want to end up hooked to a machine unless it's absolutely necessary."

Clinical Assessment & Rationale for Nephrology Referral

Mr. XXXHalperin presents a **multifactorial case of progressive CKD**, rooted primarily in long-standing diabetes and hypertensive vascular disease. His renal function has trended steadily downward over the past decade, with a more **marked acceleration in the last 12–18 months**. Despite optimized therapy with ACE inhibitors, statin, insulin, and diuretic support, his creatinine continues to rise, and **eGFR has dropped into the low 20s**, with **increasing proteinuria**, intermittent volume overload, and signs of early uremia (fatigue, poor appetite, mild cognitive slowing).

At this stage, I am concerned that we are reaching the limits of what primary care management alone can safely support. His clinical course now raises several questions that I believe would benefit from nephrology input:

1. **Etiologic Clarification**: While diabetic nephropathy remains the leading hypothesis, the **rate of decline** and **degree of proteinuria** raise concern for potential superimposed pathology. Should biopsy be considered?

2. **Dialysis Planning**: What is the appropriate timing for **pre-dialysis education** or vascular access evaluation, given his trajectory?

3. **Medication Optimization**: He is on maximum tolerated doses of lisinopril and furosemide. Would an SGLT2 inhibitor or other renally-protective agent be appropriate?

4. **Electrolyte Surveillance**: He is beginning to show mild **hyperkalemia** and has had fluctuating bicarbonate levels. How aggressively should we manage this?

5. **Nutritional Counseling**: He is losing weight slowly but has good appetite. Would a nephrology-based nutrition consult be indicated to guide **protein and phosphorus intake**?

Additional Context

Mr. XXXHalperinis a thoughtful and pragmatic individual. He expresses **willingness to consider dialysis** if strongly recommended, but hopes to avoid invasive treatment if quality of life could be preserved through medication or lifestyle-based management. He has no religious or philosophical objections to dialysis, but strongly values **independence and functional capacity**. He remains cognitively intact and emotionally stable, but has voiced anxiety about "being a burden" to his daughter.

From a systems standpoint, he is **appropriate for outpatient nephrology follow-up**, and I have encouraged him to bring a written list of medications, recent labs, and home BP/glucose logs to the appointment. A renal ultrasound is scheduled for June 18, and those results will be faxed as soon as they become available.

I believe your team is best equipped to guide this next phase of his care and help determine whether he may be a candidate for **slowing progression**, or whether **renal replacement therapy** discussions should be initiated. I appreciate your input on these key decisions, and thank you in advance for accepting this referral.

The following timeline outlines significant events in Mr. XXXHalperin's clinical history:

- In July 2023, BP ranged 150–162 mmHg; considered adjusting antihypertensives but deferred due to borderline potassium.
- In April 2025, routine monitoring continued. No urgent findings noted, but patient remained under observation for renal and cardiovascular risk factors.
- In January 2025, routine monitoring continued. No urgent findings noted, but patient remained under observation for renal and cardiovascular risk factors.
- In December 2023, anemia screening showed hemoglobin 11.7; erythropoietin level pending. No acute events reported.
- In November 2023, he agreed to nephrology referral post daughter's wedding. Mild mental fog noted.
- In April 2023, a review of his home glucose logs showed increased postprandial spikes despite insulin compliance.
- In February 2025, routine monitoring continued. No urgent findings noted, but patient remained under observation for renal and cardiovascular risk factors.
- In March 2025, routine monitoring continued. No urgent findings noted, but patient remained under observation for renal and cardiovascular risk factors.
- In September 2023, chest radiograph showed mild basilar congestion. Patient seemed more anxious and reported ‘slowing down’.
- In August 2025, routine monitoring continued. No urgent findings noted, but patient remained under observation for renal and cardiovascular risk factors.
- In August 2023, noted fatigue, exertional dyspnea, edema, echocardiogram showed diastolic dysfunction. Furosemide started.

- In November 2025, routine monitoring continued. No urgent findings noted, but patient remained under observation for renal and cardiovascular risk factors.
- In January 2023, Mr. XXXHalperinreported mild morning headaches and occasional dizziness, likely related to early blood pressure variability.
- In October 2025, routine monitoring continued. No urgent findings noted, but patient remained under observation for renal and cardiovascular risk factors.
- In December 2025, routine monitoring continued. No urgent findings noted, but patient remained under observation for renal and cardiovascular risk factors.
- In June 2025, routine monitoring continued. No urgent findings noted, but patient remained under observation for renal and cardiovascular risk factors.
- In July 2025, routine monitoring continued. No urgent findings noted, but patient remained under observation for renal and cardiovascular risk factors.
- In May 2023, his daughter accompanied him for a visit and expressed concern about his increasing fatigue and reduced appetite.
- In September 2025, routine monitoring continued. No urgent findings noted, but patient remained under observation for renal and cardiovascular risk factors.
- In March 2023, patient began reporting muscle cramps during nighttime, potentially secondary to electrolyte imbalance.
- In October 2023, creatinine reached 2.3 mg/dL; GFR dropped below 30. Discussion around nephrology referral was reinitiated.
- In June 2023, urinalysis showed a rise in protein/creatinine ratio to 1.2 g/g, consistent with worsening proteinuria.
- In May 2025, routine monitoring continued. No urgent findings noted, but patient remained under observation for renal and cardiovascular risk factors.
- In February 2023, routine labs showed a mild upward trend in creatinine to 2.0 mg/dL, which prompted earlier follow-ups.

Warm regards,

SABARI L. Ortiz, MD
Salem Family Medicine
Austin, TX
NPI: 1234567890
Phone: (512) 555-0187 | Fax: (512) 555-0199